154 results about "Myeloid cells" patented technology

Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.

Disclosed are adenovirus vectors comprising a ROBO4 enhancer / promoter operatively linked to a transgene. Also disclosed are adenovirus vectors comprising a chimeric AD5-T4 phage fibritin shaft, a trimerization domain displaying a myeloid cell-binding peptide (MBP), and a ROBO4 enhancer promoter operatively linked to a transgene. Also disclosed are methods of expressing a transgene in an endothelial cell in vivo, comprising administering to a mammal an adenovirus comprising a ROBO4 enhancer / promoter operatively linked to a transgene. Also disclosed are uses of the adenoviral vectors, including mobilization of granulocytes, monocytes and lymphocytes from bone marrow, mobilization of cancer cells in vivo, selective targeting of endothelial cells, and cancer treatment methods.

The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and / or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation.

The invention discloses a chimeric antigen receptor (CAR). The chimeric antigen receptor comprises an antigen binding structural domain (scfv) and a signal transduction structural domain, wherein thesignal transduction structural domain comprises a first conduction structural domain and a second conduction structural domain; the antigen binding structural domain is connected in series between thefirst conduction structural domain and the second conduction structural domain. When the CAR structure is stimulated by the antigen, the secretion level of cell factors of the CAR structure is extremely low; the clinical application safety can be effectively ensured; the clinical application safety is higher; the chimeric antigen receptor has higher capability of killing in-vitro antigen positivetumor cells and higher anti-tumor activity.